Svetlana A Ivanova

List of Publications by Citations

126 papers	1,160 citations	18 h-index	28 g-index
172 ext. papers	1,581 ext. citations	2.7 avg, IF	4.92 L-index

#	Paper	IF	Citations
126	New insights into the mechanism of drug-induced dyskinesia. *CNS Spectrums*, **2013**, 18, 15-20	1.8	72
125	Use of Carnosine for Oxidative Stress Reduction in Different Pathologies. *Oxidative Medicine and Cellular Longevity*, **2016**, 2016, 2939087	6.7	53
124	Circuits regulating pleasure and happiness: the evolution of reward-seeking and misery-fleeing behavioral mechanisms in vertebrates. *Frontiers in Neuroscience*, **2015**, 9, 394	5.1	51
123	Circuits regulating pleasure and happiness in major depression. *Medical Hypotheses*, **2016**, 87, 14-21	3.8	45
122	The role of the habenula in the transition from reward to misery in substance use and mood disorders. *Neuroscience and Biobehavioral Reviews*, **2017**, 80, 276-285	9	44
121	Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2009**, 33, 475-81	5.5	44
120	NMDA receptor genotypes associated with the vulnerability to develop dyskinesia. *Translational Psychiatry*, **2012**, 2, e67	8.6	40
119	Circuits Regulating Pleasure and Happiness-Mechanisms of Depression. *Frontiers in Human Neuroscience*, **2016**, 10, 571	3.3	38
118	Signs of apoptosis of immunocompetent cells in patients with depression. *Neuroscience and Behavioral Physiology*, **2007**, 37, 527-30	0.3	34
117	Missense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia. *Human Psychopharmacology*, **2010**, 25, 84-91	2.3	30
116	DNA-hydrolysing activity of IgG antibodies from the sera of patients with schizophrenia. *Open Biology*, **2015**, 5, 150064	7	23
115	Circuits regulating pleasure and happiness: evolution and role in mental disorders. *Acta Neuropsychiatrica*, **2018**, 30, 29-42	3.9	22
114	PIP5K2A-dependent regulation of excitatory amino acid transporter EAAT3. *Psychopharmacology*, **2009**, 206, 429-35	4.7	22
113	Circuits Regulating Pleasure and Happiness: The Evolution of the Amygdalar-Hippocampal-Habenular Connectivity in Vertebrates. *Frontiers in Neuroscience*, **2016**, 10, 539	5.1	22
112	Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia. *World Journal of Biological Psychiatry*, **2017**, 18, 239-246	3.8	21
111	CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects. *Bulletin of Experimental Biology and Medicine*, **2016**, 160, 687-90	0.8	21
110	Association study indicates a protective role of phosphatidylinositol-4-phosphate-5-kinase against tardive dyskinesia. *International Journal of Neuropsychopharmacology*, **2014**, 18,	5.8	19

109	The difference in serum proteomes in schizophrenia and bipolar disorder. *BMC Genomics*, **2019**, 20, 535	4.5	18
108	Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia. *Heliyon*, **2019**, 5, e02033	3.6	18
107	Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Clozapine. *Journal of Clinical Psychiatry*, **2017**, 78, e1211-e1218	4.6	18
106	Prolactin gene polymorphism (-1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics. *Schizophrenia Research*, **2017**, 182, 110-114	3.6	17
105	Circuits Regulating Pleasure and Happiness in Bipolar Disorder. *Frontiers in Neural Circuits*, **2017**, 11, 35	3.5	15
104	Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility. *World Journal of Biological Psychiatry*, **2015**, 16, 200-5	3.8	15
103	Autoimmunity and immune system dysregulation in schizophrenia: IgGs from sera of patients hydrolyze myelin basic protein. *Journal of Molecular Recognition*, **2019**, 32, e2759	2.6	14
102	An association of AKT1 gene polymorphism with antidepressant treatment response. *World Journal of Biological Psychiatry*, **2016**, 17, 239-42	3.8	13
101	Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome. *Frontiers in Psychiatry*, **2019**, 10, 803	5	13
100	A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia. *BMC Medical Genetics*, **2019**, 20, 47	2.1	12
99	Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations. *SAGE Open Medicine*, **2016**, 4, 2050312116643673	2.4	11
98	Evolution of circuits regulating pleasure and happiness with the habenula in control. *CNS Spectrums* , **2019**, 24, 233-238	1.8	11
97	The evolutionary old forebrain as site of action to develop new psychotropic drugs. *Journal of Psychopharmacology*, **2018**, 32, 1277-1285	4.6	11
96	Catalase activity of IgG antibodies from the sera of healthy donors and patients with schizophrenia. *PLoS ONE*, **2017**, 12, e0183867	3.7	10
95	Hydrolysis by catalytic IgGs of microRNA specific for patients with schizophrenia. *IUBMB Life*, **2018**, 70, 153-164	4.7	10
94	No involvement of the adenosine A2A receptor in tardive dyskinesia in Russian psychiatric inpatients from Siberia. *Human Psychopharmacology*, **2012**, 27, 334-7	2.3	10
93	Exploring Brain Derived Neurotrophic Factor and Cell Adhesion Molecules as Biomarkers for the Transdiagnostic Symptom Anhedonia in Alcohol Use Disorder and Comorbid Depression. *Frontiers in Psychiatry*, **2020**, 11, 296	5	9
92	The functional variant rs334558 of is associated with remission in patients with depressive disorders. *Pharmacogenomics and Personalized Medicine*, **2018**, 11, 121-126	2.1	9

91	Blood-Derived RNA- and microRNA-Hydrolyzing IgG Antibodies in Schizophrenia Patients. *Biochemistry (Moscow)*, **2018**, 83, 507-526	2.9	9
90	Putative role of pharmacogenetics to elucidate the mechanism of tardive dyskinesia in schizophrenia. *Pharmacogenomics*, **2019**, 20, 1199-1223	2.6	9
89	Glucose-6-phosphate dehydrogenase and catalase activities in erythrocytes of schizophrenic patients under pharmacotherapy with traditional antipsychotics. *Neurochemical Journal*, **2014**, 8, 66-70	0.5	9
88	Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2014**, 50, 172-7	5.5	9
87	Serum BDNF's Role as a Biomarker for Motor Training in the Context of AR-Based Rehabilitation after Ischemic Stroke. *Brain Sciences*, **2020**, 10,	3.4	9
86	Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of and muscarinic receptors. *World Journal of Biological Psychiatry*, **2020**, 21, 72-77	3.8	9
85	Commentary on "A non-reward attractor theory of depression": A proposal to include the habenula connection. *Neuroscience and Biobehavioral Reviews*, **2017**, 83, 736-741	9	8
84	Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and metabolic syndrome in healthy subjects and schizophrenia patients. *International Journal of Obesity*, **2018**, 42, 2036-2046	5.5	8
83	Serum Glutathione in Patients with Schizophrenia in Dynamics of Antipsychotic Therapy. *Bulletin of Experimental Biology and Medicine*, **2015**, 160, 283-5	0.8	8
82	Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression. *Frontiers in Pharmacology*, **2019**, 10, 1462	5.6	8
81	Association study of genetic markers of schizophrenia and its cognitive endophenotypes. *Russian Journal of Genetics*, **2017**, 53, 139-146	0.6	7
80	Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium. *Molecular Psychiatry*, **2019**, 24, 1099-1111	15.1	7
79	Association Between BDNF Gene Variant Rs6265 and the Severity of Depression in Antidepressant Treatment-Free Depressed Patients. *Frontiers in Psychiatry*, **2020**, 11, 38	5	7
78	Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia. *Journal of Pharmacy and Pharmaceutical Sciences*, **2018**, 21, 340-346	3.4	7
77	Association of Polymorphisms of Serotonin Transporter (5HTTLPR) and 5-HT2C Receptor Genes with Criminal Behavior in Russian Criminal Offenders. *Neuropsychobiology*, **2017**, 75, 200-210	4	7
76	Glutamate Concentration in the Serum of Patients with Schizophrenia. *Procedia Chemistry*, **2014**, 10, 80-85		7
75	5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia. *Frontiers in Molecular Neuroscience*, **2020**, 13, 63	6.1	6
74	Association between 8 P-glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug-induced hyperprolactinaemia. *British Journal of Clinical Pharmacology*, **2020**, 86, 1827-1835	3.8	6

73	Neurosteroids dehydroepiandrosterone and its sulfate in individuals with personality disorders convicted of serious violent crimes. *Bulletin of Experimental Biology and Medicine*, **2012**, 154, 89-91	0.8	6
72	Antioxidant and Immunotropic Properties of some Lithium Salts. *Journal of Applied Pharmaceutical Science*,086-089	2	6
71	Igg-Dependent Hydrolysis of Myelin Basic Protein of Patients with Different Courses of Schizophrenia. *Journal of Immunology Research*, **2020**, 2020, 8986521	4.5	6
70	Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia. *Metabolites*, **2020**, 10,	5.6	6
69	Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics. *Pharmaceuticals*, **2021**, 14,	5.2	6
68	Levodopa-Induced Dyskinesia Is Related to Indirect Pathway Medium Spiny Neuron Excitotoxicity: A Hypothesis Based on an Unexpected Finding. *Parkinson's Disease*, **2016**, 2016, 6461907	2.6	6
67	Immune System Abnormalities in Schizophrenia: An Integrative View and Translational Perspectives.. *Frontiers in Psychiatry*, **2022**, 13, 880568	5	6
66	IgG-Dependent Dismutation of Superoxide in Patients with Different Types of Multiple Sclerosis and Healthy Subjects. *Oxidative Medicine and Cellular Longevity*, **2020**, 2020, 8171020	6.7	5
65	Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome. *Diagnostics*, **2020**, 10,	3.8	5
64	Global hypomyelination of the brain white and gray matter in schizophrenia: quantitative imaging using macromolecular proton fraction. *Translational Psychiatry*, **2021**, 11, 365	8.6	5
63	Circuits Regulating Pleasure and Happiness: A Focus on Addiction, Beyond the Ventral Striatum **2016**,		5
62	Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia. *Neuropsychiatric Disease and Treatment*, **2020**, 16, 1051-1058	3.1	5
61	Neurobiological mechanisms associated with antipsychotic drug-induced dystonia. *Journal of Psychopharmacology*, **2021**, 35, 3-14	4.6	5
60	Investigating the potential role of BDNF and PRL genotypes on antidepressant response in depression patients: A prospective inception cohort study in treatment-free patients. *Journal of Affective Disorders*, **2019**, 259, 432-439	6.6	4
59	No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic-induced tardive dyskinesia. *Human Psychopharmacology*, **2019**, 34, e2685	2.3	4
58	Consider Role of Glutamatergic Habenula-projecting Globus Pallidus in OCD. *Pharmacopsychiatry*, **2019**, 52, 203-204	2	3
57	Serum levels of neurosteroids in patients with affective disorders. *Bulletin of Experimental Biology and Medicine*, **2015**, 158, 638-40	0.8	3
56	The state of the antioxidant system during therapy of patients with multiple sclerosis. *Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry*, **2011**, 5, 76-80	0.4	3

55	Spontaneous and in vitro induced apoptosis of lymphocytes and neutrophils in patients with alcohol dependence. *Bulletin of Experimental Biology and Medicine*, **2010**, 149, 246-9	0.8	3
54	Morphophenotypic predictor of the development of visceral obesity in patients with schizophrenia receiving antipsychotic therapy. *Bulletin of Siberian Medicine*, **2018**, 17, 54-64	0.4	3
53	**2018**,		3
52	Therapeutic Drug Monitoring of Olanzapine and Cytochrome P450 Genotyping in Nonsmoking Subjects. *Therapeutic Drug Monitoring*, **2020**, 42, 325-329	3.2	3
51	Genetic polymorphisms of PIP5K2A and course of schizophrenia. *BMC Medical Genetics*, **2020**, 21, 171	2.1	3
50	Genetic Polymorphisms of Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia. *Journal of Personalized Medicine*, **2021**, 11,	3.6	3
49	Features of brain activity in alcohol dependence in the task of inhibitory control. *Bulletin of Siberian Medicine*, **2021**, 19, 38-45	0.4	3
48	Remaining Need for In Vitro Test to Elucidate 5-Hydroxytryptamine 2C Receptor Functioning. *Journal of Clinical Psychopharmacology*, **2018**, 38, 410-411	1.7	3
47	Blood-Serum Glutamate in Patients with Depressive Disorders as a Potential Peripheral Marker of the Prognosis of the Effectiveness of Therapy. *Neurochemical Journal*, **2018**, 12, 366-372	0.5	3
46	Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals. *Frontiers in Psychiatry*, **2021**, 12, 661174	5	3
45	Circuits Regulating Pleasure and Happiness - Focus on Potential Biomarkers for Circuitry including the Habenuloid Complex.. *Acta Neuropsychiatrica*, **2022**, 1-36	3.9	3
44	Allele Frequencies in Depressed Patients of European Descent in Russia. *Frontiers in Genetics*, **2018**, 9, 686	4.5	2
43	Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia. *The Application of Clinical Genetics*, **2020**, 13, 97-105	3.1	2
42	The correlation between schizophrenia duration and the serum concentration of dehydroepiandrosterone sulfate. *Neurochemical Journal*, **2011**, 5, 290-293	0.5	2
41	Glutamate Level in Blood Serum of Patients with Schisophrenic Spectrum and Bipolar Affective Disorder. *Psychiatry*, **2020**, 18, 22-31	0.4	2
40	Amino acids and acylcarnitines as potential metabolomic markers of schizophrenia: new approaches to diagnostics and therapy. *Bulletin of Siberian Medicine*, **2020**, 18, 197-208	0.4	2
39	, , and as Potential Candidate Biomarker Genes for Several Clinical Subphenotypes of Depression and Bipolar Disorder. *Frontiers in Genetics*, **2020**, 11, 936	4.5	2
38	Circuits Regulating Pleasure and Happiness in Schizophrenia: The Neurobiological Mechanism of Delusions **2016**,		2

37	A genome-wide association study identifies a gene network associated with paranoid schizophrenia and antipsychotics-induced tardive dyskinesia. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2021**, 105, 110134	5.5	2
36	Clinical Evaluation of Different Treatment Strategies for Motor Recovery in Poststroke Rehabilitation during the First 90 Days. *Journal of Clinical Medicine*, **2021**, 10,	5.1	2
35	A New Paradigm to Indicate Antidepressant Treatments.. *Pharmaceuticals*, **2021**, 14,	5.2	2
34	Beta-Endorphin and Oxytocin in Patients with Alcohol Use Disorder and Comorbid Depression. *Journal of Clinical Medicine*, **2021**, 10,	5.1	2
33	Association of ANKK1 polymorphism with antipsychotic-induced hyperprolactinemia. *Human Psychopharmacology*, **2020**, 35, e2737	2.3	1
32	Proteins of the Akt1/GSK-3β signaling pathway in peripheral blood mononuclear cells of patients with affective disorders. *Neurochemical Journal*, **2014**, 8, 208-213	0.5	1
31	Effects of neuroprotector cortexin on the dynamics of neuroendocrine system parameters in patients with organic emotionally labile (asthenic) disorders. *Bulletin of Experimental Biology and Medicine*, **2013**, 155, 75-7	0.8	1
30	Conformational stability of leukocyte lactate dehydrogenase in healthy men of different age. *Bulletin of Experimental Biology and Medicine*, **2012**, 154, 44-6	0.8	1
29	Comparative efficiency of Proproten-100 during the therapy of patients with alcoholism in the stage of therapeutic remission. *Bulletin of Experimental Biology and Medicine*, **2003**, 135 Suppl 7, 171-5	0.8	1
28	Changes in immunological parameters in patients with opium abuse receiving ANAR therapy. *Bulletin of Experimental Biology and Medicine*, **2003**, 135 Suppl 7, 189-91	0.8	1
27	Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatment-free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design. *Human Psychopharmacology*, **2021**, e2826	2.3	1
26	Clinical and laboratory assessment of the effectiveness of early rehabilitation of patients with stroke using assistive robotic tools. *Bulletin of Siberian Medicine*, **2020**, 18, 55-62	0.4	1
25	Rare single nucleotide variants in COL5A1 promoter do not play a major role in keratoconus susceptibility associated with rs1536482. *BMC Ophthalmology*, **2021**, 21, 357	2.3	1
24	NEUROPHYSIOLOGICAL FEATURES OF PATIENTS WITH DIFFERENT RATES OF ALCOHOL DEPENDENCE DEVELOPMENT. *Voprosy Narkologii*, **2019**, 31-39	0.1	1
23	Using the quantitative EEG method in predicting the response to treatment of affective disorders. *V M Bekhterev Review of Psychiatry and Medical Psychology*, **2020**, 26-32	0.4	1
22	Electroencephalographic Markers of Depressive Disorders Resistance to Pharmacotherapy and Determination of a Possible Approach to Individual Prognosis of Therapy Effectiveness. *Psychiatry*, **2021**, 19, 39-45	0.4	1
21	Amino Acid and Acylcarnitine Levels in Chronic Patients with Schizophrenia: A Preliminary Study. *Metabolites*, **2021**, 11,	5.6	1
20	Preliminary Pharmacogenetic Study to Explore Putative Dopaminergic Mechanisms of Antidepressant Action. *Journal of Personalized Medicine*, **2021**, 11,	3.6	1

19	Search for Possible Associations of Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients. *Pharmacogenomics and Personalized Medicine*, **2021**, 14, 1123-1131	2.1	1
18	Characteristics of membrane-bound pool of leukocyte lactate dehydrogenase in healthy men of different age. *Human Physiology*, **2015**, 41, 444-447	0.3	0
17	Cognitive Changes in Comorbidity Alcohol Dependence and Affective Disorders. *Psychiatry*, **2020**, 18, 42-48	0.4	0
16	Sexual differences in the clinical features of antipsychotic-induced hyperprolactinemia in patients with schizophrenia. *Bulletin of Siberian Medicine*, **2019**, 18, 62-71	0.4	0
15	Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome. *Genes*, **2022**, 13, 844	4.2	0
14	Neurohumoral markers that predict the efficiency of pharmacologic therapy of depressive disorders. *Neurochemical Journal*, **2017**, 11, 185-187	0.5	
13	Antipsychotic-induced tardive dyskinesia: The role of glutamatergic system. *European Psychiatry*, **2016**, 33, S97-S97	6	
12	IgG antibodies with nuclease activity in serum of patients with schizophrenia. *European Neuropsychopharmacology*, **2017**, 27, S633-S634	1.2	
11	Study of the indices of antioxidant defense in mental maladaptation. *Human Physiology*, **2012**, 38, 543-547	0.3	
10	Effects of dehydroepiandrosterone sulfate on induced apoptosis of lymphocytes in healthy persons. *Human Physiology*, **2012**, 38, 534-538	0.3	
9	Relationship of cognitive disorders with clinical features of alcohol dependence. *Rutskij Medicinskij Zurnal*, **2020**, 62-65	0.2	
8	Molecular genetic study of clinical and cognitive features of schizophrenia: No associations with genes SOD2, GSTO1, NQO1. *Sibirskij Zurnal Klinicheskoj I Eksperimental?noj Mediciny*, **2022**, 36, 99-106	0.3	
7	Assessment of serum BDNF levels in complex rehabilitation of patients with ischemic stroke using traditional approaches to the restoration of motor functions. *Bulletin of Siberian Medicine*, **2021**, 20, 38-45	0.4	
6	Association of Polymorphic Variants of Brain-Derived Neurotrophic Factor Gene (Bdnf Rs6265) and Glutamate Transporter Gene of the Second Type (Slc1a2 Rs4354668) with the Course of Multiple Sclerosis in Patients Living in Tomsk Region. *Vestnik Rossiiskoi Akademii Meditsinskikh Nauk*, **2019**,	0.4	
5	P.568 Trihexyphenidyl in combination with antipsychotic therapy does not affect the severity of neurocognitive deficits in patients with schizophrenia. *European Neuropsychopharmacology*, **2020**, 40, S322-S323	1.2	
4	P.876 The effect of atypical antipsychotic therapy on hormonal and biochemical parameters in patients with schizophrenia. *European Neuropsychopharmacology*, **2019**, 29, S583-S584	1.2	
3	P.390 Characteristics of metabolic hormones in patients with schizophrenia with antipsychotic-induced metabolic syndrome. *European Neuropsychopharmacology*, **2019**, 29, S276-S277	1.2	
2	Peripheral Markers of Nervous Tissue Damage in Addictive and Affective Disorders. *Neurochemical Journal*, **2021**, 15, 86-90	0.5	

1	Metabolic Syndrome in a Population of In-Patients with Schizophrenia in the Western Siberia. *Psychiatry*, **2021**, 19, 52-60	0.4